Quick Answer
PLUS THERAPEUTICS, INC. reported Stockholders Equity of $4.00 million for the year ending 2025.
- PLUS THERAPEUTICS, INC. showed an increase of +144.7% in Stockholders Equity from 2024 to 2025.
- This data is from PLUS THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2014: -$5.70 million | Q1 2015: -$23.20 million | Q2 2015: $2.26 million | Q3 2015: $5.00 million | Q1 2016: $7.74 million | Q2 2016: $18.72 million | Q3 2016: $13.67 million | Q1 2017: $7.36 million | Q2 2017: $11.23 million | Q3 2017: $7.82 million | Q1 2018: $8.48 million | Q2 2018: $4.75 million | Q3 2018: $6.14 million | Q1 2019: $3.86 million | Q2 2019: -$6.28 million | Q3 2019: $160.0 thousand | Q1 2020: $85.0 thousand | Q2 2020: $3.30 million | Q3 2020: $2.62 million | Q1 2021: $9.51 million | Q2 2021: $11.95 million | Q3 2021: $14.76 million | Q1 2022: $14.64 million | Q2 2022: $9.68 million | Q3 2022: $11.40 million | Q1 2023: $2.68 million | Q2 2023: $2.66 million | Q3 2023: $2.62 million | Q1 2024: -$4.84 million | Q2 2024: -$7.63 million | Q3 2024: -$5.17 million | Q1 2025: -$23.64 million | Q2 2025: $3.03 million | Q3 2025: $5.05 million.
- Over the full 18 years of available data (2008 to 2025), PLUS THERAPEUTICS, INC.'s Stockholders Equity has grown by 151.8%.
- Historical annual values: Fiscal year 2025: $4.00 million | Fiscal year 2024: -$8.95 million | Fiscal year 2023: -$1.35 million | Fiscal year 2022: $6.45 million | Fiscal year 2021: $10.84 million | Fiscal year 2020: $3.03 million | Fiscal year 2019: $1.16 million | Fiscal year 2018: $5.23 million | Fiscal year 2017: $13.00 million | Fiscal year 2016: $10.99 million | Fiscal year 2015: $12.21 million | Fiscal year 2014: -$5.70 million | Fiscal year 2013: $3.13 million | Fiscal year 2012: $6.46 million | Fiscal year 2011: $9.95 million | Fiscal year 2010: $22.87 million | Fiscal year 2009: -$3.66 million | Fiscal year 2008: -$7.72 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: